Financial Services
Ventana Biotech, Inc.(VNTA)
Live Price
Offline$0.059
+59.46% today
1Y Change
+53.53%
Window
Jun 23, 2025 → Jun 8, 2026
- Market Cap
- —
- Revenue Growth
- +177.0%
- EPS Growth
- +300.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ventana Biotech, Inc. (VNTA) is a Financial Services stock with listed on OTC. The stock last traded around $0.06 and up 53.5% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of +177.0%, EPS growth of +300.0%, a dividend yield of 0.0%. What stands out right now is revenue +177.0%, EPS +300.0%, free cash flow 0.0% with operating margin 88.0% and ROIC 145.5%. Valuation is more restrained than many high-expectation growth names at P/E 23.1 and price/sales 0.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VNTA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+177.0% vs +3.4% peer median
Operating Margin
Above sector median
+88.0% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +177.0% and EPS at +300.0%, with operating margin around 88.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VNTA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VNTA Max Drawdown
-56.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VNTA and SPY.
Company Overview
Ventana Biotech, Inc.
Other OTC
Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.
- Leadership
- Janne Christensen
- IPO Date
- Sep 8, 2009
- Street Address
- 1 Bachstrasse
- Mailing
- Denver, 9606
- Region
- Denver, CH
- Reporting Currency
- USD
- Investor Line
- 41 44 732 60 59
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.1
- EV/EBITDA
- 1.5
- Price/Sales
- 0.9
- Price/Book
- —
Growth
- Revenue
- +177.0%
- EPS
- +300.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 88.0%
- Net Margin
- 75.2%
- ROE
- -162.1%
- ROIC
- 145.5%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.